Phase 2 N=28 Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Ovarian Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) for Use in Phase II — 10 mg/m2 IV QD x 5 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=82 Myopia Progression After Ceasing Myopia Control Contact Lens Wear
Myopia
Primary: Axial Length of the Eye — 0.080; 0.073; 0.229; 0.231 millimeter (mm)
N/A N=17 Varenicline and Nicotine Interactions in Humans (VA)
Smoking Cessation
Primary: Subjective Responses to Intravenous Nicotine — 23; 38; 51; 14 millimeters — p=<0.05
Phase 2 N=48 Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant
Graft Versus Host Disease
Primary: Percentage of Patients Alive at 6 Months — 83 percentage of patients
Phase 2 N=78 A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis
Rhinitis, Allergic, Perennial and Seasonal
Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 — 5.190; 4.071; 3.840 Scores on a scale — p=<0.0001
Phase 3 N=180 A Study of Semagacestat for Alzheimer's Patients
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 16 After Cessation of Study Drug — 6.4; 12.5; 10.5 units on a scale
N/A N=29 Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion
Otitis Media
Primary: Ear Outcome Success — 21 ears
Phase 4 N=208 Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent…
Phase 2 N=65 Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)
Constipation
Primary: Number of Participants With Inflammation of the Oral Mucosa — 31; 34; 0; 0 Particpants
Phase 4 N=20 Stress During Deep Sedation With Propofol With and Without Alfentanil
Sedation
Primary: Change in Serum Catecholamines — 87; 106 mcg/ml — p=0.940
Phase 2 N=303 A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level — 42.86; 47.69…
N/A N=211 Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
Glaucoma
Primary: Tolerability of Medications as Measured by the COMTOL Validated Instrument — 23; 50; 26; 29 percentage of patients
Phase 4 N=23 A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity 28 (DAS28) Score — -3.9 score on a scale
N/A N=3,610 Use of Telehealth In-home Messaging to Improve GI (Gastrointestinal) Endoscopy Completion Rates
Colorectal Cancer
Primary: Appointment Nonadherence-colonoscopy — 348; 333; 303 Participants
Phase 3 N=632 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL